Proleevmax™ and its role in management of chronic pain and inflammation: Clinical efficacy and trial outcomes
Bibliographic record
Abstract
Background and Aim: This clinical trial aimed to assess the clinical efficacy of Proleevamax™, a new nutraceutical supplement for the management of chronic inflammatory disorders and pain. This supplement, enriched with amino acids, supplements, and vitamins, is formulated to address neurotransmitter imbalances in chronic inflammatory conditions. The study was designed to assess safety and clinical efficacy in patients with those conditions.Methods: The study involved12 male and female patients with various chronic conditions. The participants were selected based on the preset criteria outlined in the patient information. Patients were given Proleevamax™ capsules and instructed to take 4 capsules per day, with or without food for 8 weeks. It was at the patient’s discretion whether it was taken 4 QD or 2 BID.The efficacy of Proleevamax in reducing pain and inflammation was then evaluated. This includes tracking changes in pain scores using the McGill Pain Survey and monitoring the hs-CRP test levels.Patientscompleted the patient information form and the McGill pain survey at the start of therapy, at 30 and at 60 days. Laboratory tests are done at baseline, 4 weeks, and 8 weeks.Results:(Mean CI 95%) The Proleevamax Clinical trial significantly reduced C-reactive protein levels and decreased pain intensity among participants (with a P value less than 0.05 in the change), with a P value of 0.042. This indicates that Proleevamax™ may be effective in managing chronic pain and inflammation. While the results look encouraging, further studies are recommended to confirm these results. Conclusion: Proleevamax™ has reduced pain and inflammation in the patients, as demonstrated in the trial. It reduced the C-reactive protein levels and improved pain intensity among patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.005 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".